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ABSTRACT
Background: Although gender medicine has been promoted in medical research and patient care, limited 
???????????? ???????????????????????????????????????? ??? ????????? ?????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????
eradication therapy with vonoprazan, amoxicillin, and clarithromycin.
Method: ???????????????????????????????? ???????????????????????????????????????????????? ??????????????
???? ?????????????????????????????? ??????????????????????????????????????????????????????? ?????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????
of drug-related treatment-emergent adverse events (TEAEs) were also monitored. Fisher’s exact test was used 
????????????????????????????????????????
Results: ????????????????????????????? ???? ??????????????? ?????????????????????????????? ??????????????????
??????????????????????????????????????? ??????????????????????????????????????????????????? ?????? ????????????
?????????????????????????? ?????????????????????????????????????????? ???????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
Conclusion: ???????????????????? ????????????????? ?????????? ?????????????????????? ?????????????????????
therapy with vonoprazan-based triple therapy. In particular, skin rash was observed only in females.
Keywords: ??????????????????????????????????????????????????????????????????????????????????????????
ABSTRAK
Latar belakang: Meskipun kedokteran berdasarkan jenis kelamin telah dipromosikan dalam penelitian medis 
dan pelayanan pasien, ketersediaan informasi mengenai perbedaan respon terapi eradikasi Helicobacter pylori 
lini pertama berdasarkan jenis kelamin masih terbatas. Oleh karena itu, studi retrospektif ini menginvestigasi 
perbedaan respon terapi eradikasi Helicobacter pylori lini pertama dengan vonoprazan, amoxicillin, dan 
clarithromycin berdasarkan jenis kelamin.
Metode: ?????????? ???????????????????????????????? ????????????????????????????????????? ??????????????
???? ???????????????????????????????? ??????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????
eradikasi lini pertama ditentukan dengan analisis intention-to-treat (ITT) dan per protocol (PP). Perbedaan 
berdasarkan jenis kelamin dalam angka efek samping yang muncul akibat pengobatan juga dimonitor. Uji 
Fisher’s exact digunakan untuk menilai perbedaan berdasarkan jenis kelamin. 
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Hasil: ???????????????????????????????????? ?????????????????????????? ??????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????? ??????????????? ???????????????????????????????????????????????????????????? ??????? ??????
?????? ????? ??????????????? ??????????? ??????? ?????????? ?????? ??????? ?????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
Simpulan: Lebih banyak jumlah perempuan yang mengalami efek samping akibat pengobatan dibandingkan 
laki-laki dalam terapi eradikasi Helicobacter pylori lini pertama dengan terapi tripel berbasis vonoprazan. 
??????????????????????????????????????????????????????????
Kata kunci: Helicobacter pylori, eradikasi, efek samping akibat pengobatan, perbedaan berdasarkan jenis kelamin
INTRODUCTION
Helicobacter pylori infection is associated with 
peptic ulcers and gastric cancer. The International 
Agency for Research on Cancer recommends 
population screening for H. pylori and its eradication 
to reduce the incidence of gastric cancer.1 In Japan, 
the number of patients receiving H. pylori eradication 
??????????????????????????????????????????????????????
approved for the treatment of chronic gastritis by 
???????????????????? ?????????? ?????????????????????
of antibiotics against H. pylori is enhanced by the 
coadministration of antisecretory drugs.2 Vonoprazan 
is a novel oral potassium-competitive acid blocker 
that has a greater acid-inhibitory effect than proton 
pump inhibitors (PPIs) such as esomeprazole and 
rabeprazole.3 Furthermore, the Japanese health 
insurance approved vonoprazan for H. pylori 
????????????????????? ???????????????????????????????
line H. pylori eradication therapy with vonoprazan, 
amoxicillin, and clarithromycin (vonoprazan-based 
??????????????????????????????????????????????????????
triple therapy.4
???????????????????????????????????????????????????
of drugs and occurrence of adverse drug reactions 
are recognized; furthermore, pharmacokinetic and 
pharmacodynamic changes can affect desired and 
adverse effects.5 Although gender medicine has been 
promoted in medical research and patient care, limited 
???????????? ??? ?????????? ??? ???????????? ????????????
?????????????????????????H. pylori eradication therapy. 
Therefore, this study investigated sex-specific 
??????????????????????????????????????????????????????
triple therapy for H. pylori eradication.
METHOD
This retrospective study included a total of 314 
????????????? ????????? ?????????? ?????????????????
triple therapy (20 mg vonoprazan, 750 mg amoxicillin, 
and 200 or 400 mg clarithromycin; twice daily for 
?? ?????? ??? ??????????H. pylori eradication therapy 
from March 1, 2015, to April 30, 2019, at Fuyoukai 
Murakami Hospital. H. pylori infection was diagnosed 
using the rapid urease test (PyloriTek®; Eidia, Tokyo, 
Japan). None of the patients had a history of drug 
allergy. Esophagogastroduodenoscopy confirmed 
the absence of malignancy. H. pylori eradication 
was evaluated 8 weeks after the eradication therapy 
completion using the 13C-urea breath test (UBit-100®; 
Otsuka Pharmaceutical, Tokyo, Japan), with a cut-off 
value of 2.5‰. The Institutional Ethics Committee 
approved the study, and all participants provided oral 
informed consent.
The following characteristics were analyzed 
???????? ??????? ???? ??? ??? ???????? ????????????????
atrophy (moderate or severe), nodular gastritis, history 
of peptic ulcers, and rate of study dropout. Gastric 
mucosal atrophy was diagnosed according to the 
????????????????????????????????? ???????????? ?????
moderate (C-3 or O-1), or severe (O-2 or O-3).6 First-
line eradication rates were calculated using intention-
to-treat (ITT) and per protocol (PP) analyses, and 
the rates of drug-related treatment-emergent adverse 
events (TEAEs) were recorded. Fisher’s exact test was 
????? ??? ????????? ??????????? ?????????????????????????
Statistical analysis was performed with EZR (easy R, 
version 1.37), and p values of < 0.05 were considered 
?????????????????????????7
RESULTS
The characteristics of the patients included in the 
study are summarized in Table 1. Approximately two-
third of patients (67.8%, 213/314) were males, and the 
median age of patients was 51.5 years (range, 17–78 
years). Most patients (84.1%, 264/314) had mild gastric 
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????????????????? ????? ??????????????????????????????
differences in terms of all characteristics (Table 2).
First-line eradication rates were >95% in ITT and 
??????????????????????????????? ???????????????????????
line eradication rates between males [95.3% (203/213) 
and 95.3% (203/213), respectively] and females 
[96.0% (97/101) and 96.0% (95/99), respectively] 
in ITT (p = 1.0) and PP analyses (p = 1.0) were not 
?????????????????????????????????????????????????????
???????????????????????? ???????????????????????????
than in males (4.2%, 9/213; p < 0.001). Skin rash only 
occurred in females (10.9%, 11/101; p < 0.00001; 
Table 3).
Table 3. First-line eradication rate and drug-related treatment-emergent adverse events (TEAEs) in males and females
Males (n = 213) Females (n = 101) p
First-line eradication rate
Intention-to-treat analysis 95.3% (203/213) 96.0% (97/101) 1
Per protocol analysis 95.3% (203/213) 96.0% (95/99†) 1
Drug-related TEAEs 9 (4.2%) 18 (17.8%) 0.0001
Diarrhea 3 (1.4%) 0 0.554
Dysgeusia 0 2 (2.0%) 0.103
Skin rash 0 11 (10.9%) 0.000003
Pruritus 1 (0.5%) 0 1
Dyspepsia 5 (2.3%) 3 (3.0%) 0.715
Constipation 0 1 (1.0%) 0.322
Oral candidiasis 0 1 (1.0%) 0.322
?: Fisher’s exact test
†?????????????? ????????????????????????????????????????? ?????????? ??????????????
Table 4. Characteristics of patients with skin rash
Age (years) Sex Interval from start of treatmentto onset (days) Clarithromycin dosage Eradication
Patient 1 60 Female 2 200 mg twice daily Success
Patient 2 54 Female 3 200 mg twice daily Success
Patient 3 60 Female 3 200 mg twice daily Success
Patient 4 36 Female 7 200 mg twice daily Success
Patient 5 41 Female 8 200 mg twice daily Success
Patient 6 71 Female 8 200 mg twice daily Success
Patient 7 29 Female 9 200 mg twice daily Success
Patient 8 40 Female 9 200 mg twice daily Success
Patient 9 55 Female 9 200 mg twice daily Success
Patient 10 50 Female 10 200 mg twice daily Success
Patient 11 60 Female 10 200 mg twice daily Success
Table 1. Characteristics of the study patients (n = 314)
Age (years) 51.5 (43, 59)*
Males 213 (67.8%)
Gastric mucosal atrophy
Mild 264 (84.1%)
Moderate 30 (9.6%)
Severe 20 (6.4%)
Nodular gastritis 13 (4.1%)
Past history of peptic ulcers 56 (17.8%)
Dropouts 2 (0.6%)
*: median (25%, 75%)
Table 2. Characteristics of males and females
Males  
(n = 213) 
n (%)
Females  
(n = 101) 
n (%)
p*
Age
?????????? 20 (9.4) 12 (11.9) 0.550
Gastric mucosal atrophy
Moderate or severe 34 (16.0) 16 (15.8) 1
Nodular gastritis 6 (2.8) 7 (6.9) 0.126
Past history of peptic ulcers 43 (20.2) 13 (12.9) 0.155
Dropouts 0 2 (2.0) 0.103
*: Fisher’s exact test
DISCUSSION
First-line eradication rates observed in the 
present study were 2.7–3.4% higher than those 
(92.6%; 300/324) reported in a Japanese multicenter, 
prospective study.8 First-line vonoprazan-based triple 
therapy is recommended as a highly effective regimen 
regardless of sex because it exceeds the goal of > 90% 
eradication established as a global consensus for H. 
pylori treatment in the era of increasing antibiotic 
resistance.9 Drug-related TEAEs were observed in 
8.6% of patients (27/314), and the dropout rate was 
0.6% (2/314), consistent with the values reported in a 
???????????????????????????????????????????????????
of vonoprazan-based triple therapy for H. pylori 
eradication, which reported a pooled TEAE of 8.1% 
and pooled dropout rate due to TEAEs of 0.5%.10 Two 
patients who discontinued treatment because of rash 
or epigastralgia with acute mid-grade fever 2 days 
after the initiation of treatment achieved bacterial 
eradication. Extremely early eradication of H. pylori 
????????????????????????????????????????????????????
the death of H. pylori, which is known as Jarisch–
Herxheimer reaction.
???????????????????????????????????????????????????
in terms of the development of skin rash. Males and 
females differ in their pharmacological responses; 
thus, females have a higher incidence of allergic skin 
rash.5 In addition, 63.6% of patients (7/11) presented 
??????????????????????????H. pylori eradication therapy 
????????????????????????????????????????????????????????H. 
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pylori immune reaction in patients with skin rash after 
H. pylori eradication therapy completion, suggesting 
that skin rash is not necessarily a drug-related TEAE.11 
???????????????????????????????????????????? ????????
result in differential susceptibility of males and females 
to skin reactions as well as autoimmune diseases. It 
??? ?????? ????????? ??? ????????? ???? ?????? ??? ????? ??????
particularly in patients using antibiotics.11 However, it 
is important to distinguish other causes of adverse drug 
reactions because the appropriate use of antibiotics is 
limited if physicians overestimate antibiotic-associated 
adverse drug reactions.
The present study has several limitations. This study 
was designed as a single-center retrospective study. 
Therefore, large-scale surveys are necessary in the 
future. Further, drug-induced lymphocyte stimulation 
test was not performed. Further investigation of the 
cause of skin rash is needed.
CONCLUSION
????????????????????????????????????????????????
higher in females than in males during first-line 
H. pylori eradication with vonoprazan-based triple 
therapy, particularly skin rash.
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